Uppsala 31st May 2018


New positive results from animal study

Nanexa has obtained results from a week-long animal study conducted during the month of May. The study was done on rats that were injected subcutaneously with a model drug that was provided with a further development of Nanexa’s drug delivery system PharmaShell®.

The new results show interesting and positive properties of PharmaShell® during the first time after administration.

Nanexa’s CEO David Westberg comments:

With the new animal study results, we further confirm that PharmaShell® is a drug delivery system with unique characteristics. We have the opportunity to control several parameters that are important for creating effective and safe medicines. The properties of PharmaShell® that the study demonstrated are also valuable for the drug project focused on oncology that we will run under our own control.

I look forward with confidence to communicating the new results with the pharmaceutical companies we have contact with.


For further information:

Nanexa AB (publ)

David Westberg, VD

Phone: +46 709 42 83 03

E mail:


About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a